INTRODUCTION {#sec1-1}
============

Lung cancer is the most common type of cancer worldwide and represents a leading cause of cancer-related mortality.[@ref1]-[@ref3] It has been suggested that genetic variations of cancer-related genes could play a role in influencing individual susceptibility to lung cancer.[@ref4],[@ref5] Among the many candidate genes, polymorphisms within inflammatory responsegenes have received increasing attention in the past few years, since inflammation has been strongly implicated in carcinogenesis.[@ref6]-[@ref8]

The nuclear factor-kappa B (NF-κB) family constitutes a group of transcription factors which serve as important mediators in inflammatory responses. In addition to inflammatory responses, a wide range of signal transduction processes converge on the NF-κB pathway, including cell proliferation, apoptosis, angiogenesis and many others.[@ref9] The p105/p50 isoforms of the NF-κBfamily, denoted NF-κB1, represents the most ubiquitous form of transcription factor in the family. Given the important role of NF-κB1 as the central hub of many biological processes, it is closely regulated by its endogenous inhibitors IκBα under normal conditions.[@ref10] NF-κB1 and IκBα are encoded by the *NFKB1* and *NFKBIA* genes respectively, and it has been shown that disrupted expressions of these genes can result in carcinogenesis.[@ref11]-[@ref13]

Functional polymorphisms within the promoter region of these genes could potentially influence the levels of the proteins encoded. These functional polymorphisms may therefore contribute to the inter individual differences in lung cancer risk. To test our hypothesis, we conducted a case-control study to investigate the association of *NFKB1* -94 ins/del ATTG polymorphism and *NFKBIA* -826C\>T and -881A\>G polymorphisms with the risk of lung cancer in a Chinese population.

METHODS {#sec1-2}
=======

Study Population {#sec2-1}
----------------

718 lung cancer patients and 718controls participated in this retrospective case-control study. The participants were recruited between September 2011 andAugust 2014 fromthe Zhengzhou Central Hospital Affiliated to Zhengzhou University. Controls were cancer-free individuals randomly selected from a cancer screening program, and were matched (in frequency) to cases by age, sex and smoking behavior. The study was approved by the Research Review and Ethics Board of Zhengzhou Central Hospital Affiliated to Zhengzhou University(Approval number: 21234/RESP/43.2011). Written informed consent was obtained from all the participants prior to the study.

Genotyping {#sec2-2}
----------

Genotyping was performed by using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method ([Fig.1](#F1){ref-type="fig"})described elsewhere using the Life Express thermocycler (Bioer, China), and the genotypes were confirmed by sequencing 10% of the PCR products.[@ref14],[@ref15]

![Gel image of PCR-RFLP. From left to right, NFKB1 del/del, NFKB1 ins/ins, NFKB1 ins/del, NFKBIA -826TT, NFKBIA -826CC, NFKBIA -826CT, NFKBIA -881AA, NFKBIA -881GG, NFKBIA -881AG.](PJMS-31-1411-g001){#F1}

Statistical Analysis {#sec2-3}
--------------------

Differences in age, smoking status and gender between cases and controls were evaluated using the chi-square test. The association between the polymorphisms and lung cancer risk was determined using the logistic regression method to assess the odds ratio (OR). P values less than 0.05 were considered statistically significant.

RESULTS {#sec1-3}
=======

Association of NFKB1 and NFKBIA polymorphisms with lung cancer risk {#sec2-4}
-------------------------------------------------------------------

The association between *NFKB1* and *NFKBIA* polymorphisms and lung cancer risk is shown in [Table-I](#T1){ref-type="table"}. By using ins/ins genotype as the reference, the heterozygous and homozygous variant genotypes of the *NFKB1* polymorphism were found to be significantly associated with the reduced risk of lung cancer(P=0.002 for heterozygous, P\<0.001 for variant). On the other hand, the heterozygous and homozygous variant genotypes of the *NFKBIA* polymorphisms appeared to be significantly associated with increased lung cancer risk(P=0.046 for -826CT, P=0.013 for -826TT, P=0.031 for -881AG, P=0.008 for -881GG,).

###### 

Association between NFKB1 -94 ins/del ATTG polymorphism, NFKBIA -826C\>Tpolymorphism and NFKBIA -881A\>G polymorphism and lung cancer risk.

  Genotype           Case, N=718   Control, N=718   OR (95% CI)           P
  ------------------ ------------- ---------------- --------------------- -----------------------------------------
  -94 ins/del ATTG                                                        
   Ins/ins           434(60.4%)    352(49.0%)       1.000                 \-
   Ins/del           252(35.1%)    290(40.4%)       0.705 (0.566-0.878)   0.002[\*](#t1f1){ref-type="table-fn"}
   Del/del           32(4.5%)      76(10.6%)        0.342 (0.221-0.528)   \<0.001[\*](#t1f1){ref-type="table-fn"}
  -826C\>T                                                                
   CC                413(57.5%)    461(64.2%)       1.000                 \-
   CT                251(35.0%)    223(31.1%)       1.256 (1.004-1.572)   0.046[\*](#t1f1){ref-type="table-fn"}
   TT                54(7.5%)      34(4.7%)         1.773 (1.131-2.778)   0.013[\*](#t1f1){ref-type="table-fn"}
  -881A\>G                                                                
   AA                402(56.0%)    454(63.2%)       1.000                 \-
   AG                257(35.8%)    227(31.6%)       1.277 (1.023-1.599)   0.031[\*](#t1f1){ref-type="table-fn"}
   GG                59(8.2%)      37(5.2%)         1.801 (1.169-2.775)   0.008[\*](#t1f1){ref-type="table-fn"}

significant.

Combinations of polymorphisms and lung cancer risk {#sec2-5}
--------------------------------------------------

The association of combinations of *NFKB1* -94 ins/del ATTG polymorphism and *NFKBIA* -826C\>T polymorphism with lung cancer risk is shown in [Table-II](#T2){ref-type="table"}. Of the nine possible combinations, significant risk association was observed only for ins/del-CC(P=0.006), del/del-CC(P\<0.001), and del/del-CT (P=0.003)combination genotypes. All the three combination genotypes showed decreased risk association.

###### 

Association between combinations of NFKB1 -94 ins/del ATTG polymorphism and NFKBIA -826C\>T polymorphism and lung cancer risk.

  Genotype           Case       Control       OR (95% CI)   P                      
  ------------------ ---------- ------------- ------------- ---------------------- -----------------------------------------
  -94 ins/del ATTG   -826C\>T                                                      
   Ins/ins           CC         259 (36.1%)   232 (32.3%)   1.000                  \--
   Ins/del           CC         134 (18.7%)   179 (24.9%)   0.671 (0.504-0.892)    0.006[\*](#t2f1){ref-type="table-fn"}
   Del/del           CC         20 (2.8%)     50 (7.0%)     0.358 (0.207-0.620)    \<0.001[\*](#t2f1){ref-type="table-fn"}
   Ins/ins           CT         144 (20.1%)   103 (14.3%)   1.252 (0.920-1.705)    0.153
   Ins/del           CT         99 (13.8%)    95 (13.2%)    0.934 (0.669-1.302)    0.685
   Del/del           CT         8 (1.1%)      25 (3.5%)     0.287 (0.127-0.648)    0.003[\*](#t2f1){ref-type="table-fn"}
   Ins/ins           TT         31 (4.3%)     17 (2.4%)     1.633 (0.881-3.029)    0.119
   Ins/del           TT         19 (2.6%)     16 (2.2%)     1.064 (0.535-2.117)    0.860
   Del/del           TT         4 (0.6%)      1 (0.1%)      3.583 (0.398-32.288)   0.255

significant.

Association between combinations of *NFKB1* -94 ins/del ATTG polymorphism and *NFKBIA* -881A\>G polymorphism and lung cancer risk is shown in [Table-III](#T3){ref-type="table"}. Similar to the above, three combinations showed significantly decreased risk association with lung cancer, namely ins/del-AA(P=0.004), del/del-AA (P\<0.001)and del/del-AG (P=0.001)genotypes.

###### 

Association between combinations of NFKB1 -94 ins/del ATTG polymorphism and NFKBIA -881A\>G polymorphism and lung cancer risk.

  Genotype           Case       Control       OR (95% CI)   P                     
  ------------------ ---------- ------------- ------------- --------------------- -----------------------------------------
  -94 ins/del ATTG   -881A\>G                                                     
   Ins/ins           AA         254 (35.4%)   228 (31.8%)   1.000                 \--
   Ins/del           AA         128 (17.8%)   176 (24.5%)   0.653 (0.489-0.872)   0.004[\*](#t3f1){ref-type="table-fn"}
   Del/del           AA         20 (2.8%)     50 (7.0%)     0.359 (0.208-0.621)   \<0.001[\*](#t3f1){ref-type="table-fn"}
   Ins/ins           AG         148 (20.6%)   105 (14.6%)   1.265 (0.930-1.721)   0.134
   Ins/del           AG         103 (14.3%)   98 (13.6%)    0.943 (0.679-1.311)   0.729
   Del/del           AG         6 (0.8%)      24 (3.3%)     0.224(0.090-0.559)    0.001[\*](#t3f1){ref-type="table-fn"}
   Ins/ins           GG         32(4.5%)      19 (2.6%)     1.512(0.834-2.741)    0.174
   Ins/del           GG         21 (2.9%)     16 (2.2%)     1.178 (0.600-2.313)   0.634
   Del/del           GG         6 (0.8%)      2 (0.3%)      2.693(0.538-13.476)   0.228

significant.

The combinations of *NFKBIA* -826C\>T polymorphism and *NFKBIA* -881A\>G polymorphism and their association with lung cancer risk is shown in [Table-IV](#T4){ref-type="table"}. Of the nine possible combinations, two combinations showed significantly increased risk association, namely CT-AG (P=0.043)and TT-GG (P=0.017)genotypes.

###### 

Association between combinations of NFKBIA -826C\>T polymorphism and NFKBIA -881A\>G polymorphism and lung cancer risk.

  Genotype   Case       Control       OR (95% CI)   P                      
  ---------- ---------- ------------- ------------- ---------------------- ---------------------------------------
  -826C\>T   -881A\>G                                                      
   CC        AA         400 (55.7%)   452 (63.0%)   1.000                  \--
   CT        AA         2 (0.3%)      2 (0.3%)      1.130(0.158-8.059)     0.903
   TT        AA         0 (0.0%)      0 (0.0%)      \-\--                  \--
   CC        AG         8 (1.1%)      6 (0.8%)      1.507(0.518-4.380)     0.452
   CT        AG         246 (34.3%)   220 (30.6%)   1.264(1.008-1.584)     0.043[\*](#t4f1){ref-type="table-fn"}
   TT        AG         3 (0.4%)      1 (0.1%)      3.390 (0.351-32.722)   0.291
   CC        GG         5 (0.7%)      3 (0.4%)      1.883(0.447-7.931)     0.388
   CT        GG         3 (0.4%)      1 (0.1%)      3.390 (0.351-32.722)   0.291
   TT        GG         51 (7.1%)     33 (4.6%)     1.746(1.105-2.761)     0.017[\*](#t4f1){ref-type="table-fn"}

significant.

Analysis of NFKB1 risk association by gender and smoking status {#sec2-6}
---------------------------------------------------------------

The stratified association between the *NFKB1* polymorphism and lung cancer risk according to gender and smoking status is shown in [Table-V](#T5){ref-type="table"}. The heterozygote genotype appeared to decrease the risk of lung cancer among females(P=0.005), but not males. However, the variant genotype decreased the lung cancer risk both in males(P=0.004) and females(P\<0.001). The heterozygous genotype was also associated witha decreased risk of lung cancer among smokers(P=0.003), but not non-smokers. The variant genotype was associated with decreased lung cancer risk in both smokers (P\<0.001)and non-smokers(P=0.001).

###### 

Association between NFKB1 -94 ins/del ATTG polymorphism and lung cancer risk according to sex and smoking status.

  Genotype     Case          Control       OR (95% CI)           P
  ------------ ------------- ------------- --------------------- -----------------------------------------
  Male                                                           
   Ins/ins     220 (58.8%)   188 (50.3%)   1.000                 \--
   Ins/del     137 (36.6%)   150 (40.1%)   0.781 (0.577-1.056)   0.108
   Del/del     17 (4.5%)     36 (9.6%)     0.404 (0.220-0.742)   0.004[\*](#t5f1){ref-type="table-fn"}
  Female                                                         
   Ins/ins     214 (62.2%)   164 (47.7%)   1.000                 \--
   Ins/del     115 (33.4%)   140 (40.7%)   0.630 (0.457-0.867)   0.005[\*](#t5f1){ref-type="table-fn"}
   Del/del     15 (4.4%)     40 (11.6%)    0.287 (0.154-0.538)   \<0.001[\*](#t5f1){ref-type="table-fn"}
  Smoker                                                         
   Ins/ins     234 (60.2%)   181 (46.5%)   1.000                 \--
   Ins/del     135 (34.7%)   164 (42.2%)   0.637 (0.472-0.859)   0.003[\*](#t5f1){ref-type="table-fn"}
   Del/del     20 (5.1%)     44 (11.3%)    0.352 (0.200-0.617)   \<0.001[\*](#t5f1){ref-type="table-fn"}
  Non-smoker                                                     
   Ins/ins     200 (60.8%)   171 (52.0%)   1.000                 \-\--
   Ins/del     117 (35.6%)   126 (38.3%)   0.794 (0.574-1.098)   0.163
   Del/del     12 (3.6%)     32 (9.7%)     0.321 (0.160-0.642)   0.001[\*](#t5f1){ref-type="table-fn"}

significant.

Analysis of NFKBIA -826C\>T risk association by gender and smoking status {#sec2-7}
-------------------------------------------------------------------------

The association between *NFKBIA* -826C\>T polymorphism and lung cancer risk according to sex and smoking status is shown in [Table-VI](#T6){ref-type="table"}.. Interestingly, the risk association of the heterozygous and variant genotypes appeared to be lost after stratification by gender and smoking status.

###### 

Association between NFKBIA -826C\>T polymorphism and lung cancer risk according to sex and smoking status.

  Genotype     Case          Control       OR (95% CI)           P
  ------------ ------------- ------------- --------------------- -------
  Male                                                           
   CC          215 (57.5%)   241 (64.4%)   1.000                 \-\--
   CT          133 (35.6%)   116 (31.0%)   1.285 (0.943-1.752)   0.112
   TT          26 (7.0%)     17 (4.5%)     1.714 (0.905-3.246)   0.098
  Female                                                         
   CC          198 (57.6%)   220 (64.0%)   1.000                 \-\--
   CT          118 (34.3%)   107 (31.1%)   1.225 (0.886-1.695)   0.220
   TT          28 (8.1%)     17 (4.9%)     1.830 (0.972-3.445)   0.061
  Smoker                                                         
   CC          219 (56.3%)   245 (63.0%)   1.000                 \-\--
   CT          138 (35.5%)   124 (31.9%)   1.245 (0.919-1.686)   0.157
   TT          32 (8.2%)     20 (5.1%)     1.790 (0.995-3.222)   0.052
  Non-smoker                                                     
   CC          194 (59.0%)   216 (65.7%)   1.000                 \-\--
   CT          113 (34.3%)   99 (30.1%)    1.271 (0.912-1.772)   0.157
   TT          22 (6.7%)     14 (4.3%)     1.750 (0.871-3.515)   0.116

significant.

Analysis of NFKBIA -881A\>G risk association by gender and smoking status {#sec2-8}
-------------------------------------------------------------------------

The association between *NFKBIA* -881A\>G polymorphism and the risk of lung cancer according to sex and smoking status is shown in [Table-VII](#T7){ref-type="table"}. Similar to the *NFKBIA* -826C\>T polymorphism, no association was observed for the heterozygous and variant genotypes and lung cancer risk in both males and females after stratification by sex. However, after stratification by smoking status, significant association was observed only for the variant genotype with lung cancer risk among smokers(P=0.032).

###### 

Association between NFKBIA -881A\>G polymorphism and lung cancer risk according to sex and smoking status.

  Genotype     Case          Control       OR (95% CI)           P
  ------------ ------------- ------------- --------------------- ---------------------------------------
  Male                                                           
   AA          208 (55.6%)   235 (62.8%)   1.000                 \-\--
   AG          136 (36.4%)   120 (32.1%)   1.280 (0.941-1.743)   0.116
   GG          30 (8.0%)     19 (5.1%)     1.784 (0.975-3.264)   0.060
  Female                                                         
   AA          194 (56.4%)   219 (63.7%)   1.000                 \-\--
   AG          121 (35.2%)   107 (31.1%)   1.277 (0.923-1.765)   0.140
   GG          29 (8.4%)     18 (5.2%)     1.819 (0.979-3.378)   0.058
  Smoker                                                         
   AA          214 (55.0%)   240 (61.7%)   1.000                 \-\--
   AG          140 (36.0%)   128 (32.9%)   1.227 (0.907-1.660)   0.185
   GG          35 (9.0%)     21 (5.4%)     1.869 (1.055-3.310)   0.032[\*](#t7f1){ref-type="table-fn"}
  Non-smoker                                                     
   AA          188 (57.1%)   214 (65.0%)   1.000                 \-\--
   AG          117 (35.6%)   99 (30.1%)    1.345 (0.966-1.874)   0.080
   GG          24 (7.3%)     16 (4.9%)     1.707 (0.881-3.311)   0.113

significant.

DISCUSSION {#sec1-4}
==========

Given the important role of NF-κB and IκB in diverse biological pathways, genetic variations within key genes of the NF-κB pathway could obstruct the normal functioning of the protein products which in turn influences the risk of cancers. The *NFKB1* -94 ins/del ATTG, *NFKBIA* -826C\>T and *NFKBIA* -881A\>G polymorphisms have been described. These functional polymorphisms have been shown to affect the level of the proteins produced, with the deletion allele, T allele and G allele of the three polymorphisms are associated with the reduced production of the respective proteins products.[@ref16],[@ref17]

We have showed that the variant del genotype of the *NFKB1* -94 ins/del ATTG polymorphism could significantly reduce lung cancerrisk. Our results are in disagreement with those reported by Huang et al.[@ref18] who found no association between the *NFKB1* polymorphism and lung cancer risk in a Chinese population. However, our results concur with Huo et al.[@ref19] who investigated the association of the polymorphism with ovarian cancer among Chinese.

We have also showed in the current study that the variant genotypes of *NFKBIA* -826C\>T and -881A\>G polymorphisms could increase lung cancerrisk. Similar to the *NFKB1* -94 ins/del ATTG polymorphism, our results are contrary to the results of Huang et al.[@ref18] who also found no association between the -826C\>T polymorphism and lung cancer risk. However, when stratified by gender, we found that our results concur with the former, in that there was a lack of association of the polymorphism and cancer risk in both males and females. A similar lack of association was observed when stratified by smoking status, with the exception of *NFKBIA* -881GG variant genotype among smokers. This was in partial agreement with Umar et al.[@ref20] who found that the CT and CT+TT genotype of the -826C\>T polymorphism was associated with a decreased risk of esophageal squamous cell carcinoma in an Indian population. On the other hand, Lin et al.[@ref21] showed that the heterozygous genotype of both the *NFKBIA* -826C\>T and -881A\>G polymorphisms increased the risk of oral cancer among Chinese. The disagreements among the findings reported in the literature could be due to the different backgrounds (age, sex, ethnic group, smoking status and geography) of the study subjects recruited, as well as the properness of subject matching.

The strengths of this study are: (i) it is the first study which establishes an association between the polymorphism and lung cancer risk in China, and (ii) it was conducted in a relatively properly-matched population. However, the limitation is that only three SNPs were analyzed.

CONCLUSION {#sec1-5}
==========

We have showed that the variant alleles of *NFKB1* -94 ins/del ATTG polymorphism, *NFKBIA* -826C\>T polymorphism and *NFKBIA* -881A\>G polymorphism could influence the risk of lung cancer in China.
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